Market closed

Cara Therapeutics/CARA

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Cara Therapeutics

Cara Therapeutics Inc is a development-stage biotechnology company involved in the development of novel therapeutics to treat human diseases associated with inflammation, pain, and pruritus. Cara's most advanced compound, CR845, aims to treat acute pain and pruritus. This patented compound has analgesic, anti-inflammatory, and antipruritic properties that can be used for multiple therapeutic applications. Additionally, Cara's objective is to use its proprietary drug-screening technology to develop a future pipeline of first-in-class molecules with analgesic and anti-inflammatory features.

Ticker

CARA
Trading on

Industry

Pharmaceuticals

Employees

55

CARA Metrics

BasicAdvanced
$14M
Market cap
-
P/E ratio
-$2.04
EPS
0.69
Beta
-
Dividend rate
$14M
0.69
$1.68
$0.24
347K
4.594
4.204
405.208
406.656
-23.35%
-63.43%
-184.32%
1.27
1.21
1.21
-0.168
-59.53%
-1.67%
-55.32%
128.98%

What the Analysts think about CARA

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Cara Therapeutics stock.

CARA Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

CARA Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy CARA

$

Sign up or log in to buy
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Cara Therapeutics stock?

Cara Therapeutics (CARA) has a market cap of $14M as of October 10, 2024.

What is the P/E ratio for Cara Therapeutics stock?

The price to earnings (P/E) ratio for Cara Therapeutics (CARA) stock is 0 as of October 10, 2024.

Does Cara Therapeutics stock pay dividends?

No, Cara Therapeutics (CARA) stock does not pay dividends to its shareholders as of October 10, 2024.

When is the next Cara Therapeutics dividend payment date?

Cara Therapeutics (CARA) stock does not pay dividends to its shareholders.

What is the beta indicator for Cara Therapeutics?

Cara Therapeutics (CARA) has a beta rating of 0.69. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.